Diabetes drug shows promise against rectal cancer in new trial

NCT ID NCT02437656

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether adding metformin, a common diabetes medicine, to standard chemo and radiation therapy could help people with locally advanced rectal cancer. 60 adults with stage T3 or T4 rectal cancer took part. The main goal was to see if the combination led to a complete disappearance of cancer cells in the tumor after surgery.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECTAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

rectal cancer rectal neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Centre Galilée - Hôpital Privé La Louvière

    Lille, 59045, France

  • Centre Gray

    Maubeuge, 59600, France

  • Centre Hospitalier

    Lens, 62300, France

  • Centre Joliot-Curie

    Saint-Martin-Boulogne, 62200, France

  • Centre Léonard de Vinci - SARL du pont Saint Vaast

    Douai, 59500, France

  • Centre Marie Curie

    Arras, 62000, France

  • Centre Oscar Lambret

    Lille, 59020, France

  • Centre Pierre Curie

    Beuvry, 62880, France

  • Clinique des Dentellières

    Valenciennes, 59300, France

  • Clinique du Bois - Centre Bourgogne

    Lille, 59000, France

  • Institut André Dutreix

    Dunkirk, 59240, France